The biotechnology bubble machine

Nature Biotechnology

Volumn 21, Issue 4, 2003, Pages 355-356

  Rasnick, David ^a  

^a Boveran   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; REAGENT; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT HUMAN INSULIN; RECOMBINANT INTERFERON; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTHRITIS; BIOINFORMATICS; BIOTECHNOLOGY; BONE MARROW; BONE MARROW TOXICITY; CANCER; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC ASPECT; ECONOMIC DEVELOPMENT; EQUIPMENT; FOOD AND DRUG ADMINISTRATION; GENE MAPPING; GENE THERAPY; HEALTH; HEALTH CARE; HEMOPHILIA; HUMAN; MEDICAL RESEARCH; MONEY; NONHUMAN; NOTE; PHYSICIAN; PRIORITY JOURNAL; SCIENCE;

BIOTECHNOLOGY; COMMERCE; ENTREPRENEURSHIP; FORECASTING; GENETIC ENGINEERING; INDUSTRY; UNITED STATES;

EID: 0037382948     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0403-355     Document Type: Note

References (9)

1. The Biotech Advisor (Charter Financial Publishing Network, Shrewsbury, NJ, 2002).
2. Ackerman, J. A promise unfulfilled in biotechnology: decline and fall of Alpha-Beta speaks volumes about pitballs of industry. The Boston Globe, February 10 (1999).
3. , Leonhardt, D. Northeast Quietly Becomes a Health Care Corridor. New York Times, December 30 (2002).
4. http://www.bio.org/news/stats.asp
5. Lähteenmäki, R. & Fletcher, L. Nat. Biotechnol. 21, 551-555 (2002).
6. Feldbaum, C. B., Convergence: Ernst & Young's Biotechnology Industry Report, Millennium Edition (E&Y, New York, 2000).
7. http://www.bio.org/er/approveddrugs.asp
8. Lee, K.L., et al. Ann. Intern. Med. 120, 876-885 (1994).
9. Federal Trade Commission. Resolving Anticompetitive Concerns, FTC Clears $16 Billion Acquisition of Immunex Corp. by Amgen Inc. (FTC, Washington, DC, 2002).